Is ANVS or APLT more profitable?

Annovis Bio's return on equity of -318.08% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% Applied Therapeutics N/A -340.84% -175.00%

Is APLT or CING more profitable?

Applied Therapeutics' return on equity of -340.84% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Cingulate N/A -365.15% -158.55%

Does the media favor APLT or CING?

In the previous week, Applied Therapeutics and Applied Therapeutics both had 1 articles in the media. Applied Therapeutics' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer APLT or CRDF?

In the previous week, Cardiff Oncology had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for Cardiff Oncology and 1 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, APLT or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Applied Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Applied Therapeutics $1M 15.86 -$105.62M -$0.10 N/A OKYO Pharma N/A N/A -$4.71M N/A N/A

Is APLT or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% OKYO Pharma N/A N/A N/A

Does the media prefer APLT or OKYO?

In the previous week, OKYO Pharma had 8 more articles in the media than Applied Therapeutics. MarketBeat recorded 9 mentions for OKYO Pharma and 1 mentions for Applied Therapeutics. OKYO Pharma's average media sentiment score of 0.26 beat Applied Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OKYO Pharma 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TCRX or APLT?

In the previous week, TScan Therapeutics had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Applied Therapeutics. TScan Therapeutics' average media sentiment score of 0.45 beat Applied Therapeutics' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Applied Therapeutics (APLT) Competitors

$0.10 0.00 (0.00%)

As of 07/20/2026

Compare

APLT vs. ANVS, CING, CRDF, OKYO, and TCRX

Should you buy Applied Therapeutics stock or one of its competitors? MarketBeat compares Applied Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Applied Therapeutics include Annovis Bio (ANVS), Cingulate (CING), Cardiff Oncology (CRDF), OKYO Pharma (OKYO), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry.

How does Applied Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Annovis Bio has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

In the previous week, Applied Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 1 mentions for Applied Therapeutics and 0 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
Annovis Bio	Neutral
Applied Therapeutics	Neutral

Annovis Bio has higher earnings, but lower revenue than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Annovis Bio's return on equity of -318.08% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Applied Therapeutics	N/A	-340.84%	-175.00%

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Annovis Bio presently has a consensus target price of $11.67, indicating a potential upside of 564.77%. Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Annovis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Annovis Bio and Applied Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Applied Therapeutics compare to Cingulate?

Applied Therapeutics (NASDAQ:APLT) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.91, meaning that its share price is 191% less volatile than the broader market.

Applied Therapeutics' return on equity of -340.84% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Cingulate	N/A	-365.15%	-158.55%

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Applied Therapeutics and Applied Therapeutics both had 1 articles in the media. Applied Therapeutics' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Applied Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cingulate	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Cingulate has a consensus price target of $27.33, indicating a potential upside of 477.87%. Given Applied Therapeutics' higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cingulate has lower revenue, but higher earnings than Applied Therapeutics. Cingulate is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Summary

Applied Therapeutics beats Cingulate on 7 of the 12 factors compared between the two stocks.

How does Applied Therapeutics compare to Cardiff Oncology?

Applied Therapeutics (NASDAQ:APLT) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 8.5% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cardiff Oncology has lower revenue, but higher earnings than Applied Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Cardiff Oncology	$590K	99.27	-$45.85M	-$0.67	N/A

Applied Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

In the previous week, Cardiff Oncology had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for Cardiff Oncology and 1 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Applied Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 777.19%. Given Applied Therapeutics' higher probable upside, research analysts clearly believe Applied Therapeutics is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Summary

Cardiff Oncology beats Applied Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to OKYO Pharma?

Applied Therapeutics (NASDAQ:APLT) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Applied Therapeutics presently has a consensus price target of $1.00, suggesting a potential upside of 870.87%. OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 301.89%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, OKYO Pharma had 8 more articles in the media than Applied Therapeutics. MarketBeat recorded 9 mentions for OKYO Pharma and 1 mentions for Applied Therapeutics. OKYO Pharma's average media sentiment score of 0.26 beat Applied Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Applied Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OKYO Pharma	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

OKYO Pharma has lower revenue, but higher earnings than Applied Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A

Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

OKYO Pharma's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
OKYO Pharma	N/A	N/A	N/A

Summary

OKYO Pharma beats Applied Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Applied Therapeutics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

TScan Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Applied Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Applied Therapeutics	N/A	-340.84%	-175.00%

Applied Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	5.91	-$129.77M	-$0.96	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

TScan Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 542.40%. Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, TScan Therapeutics had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Applied Therapeutics. TScan Therapeutics' average media sentiment score of 0.45 beat Applied Therapeutics' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Applied Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TScan Therapeutics beats Applied Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Applied Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLT vs. The Competition

Export

Metric	Applied Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.86M	$3.64B	$6.80B	$12.37B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.03	20.71	27.09	24.07
Price / Sales	15.86	302.58	520.26	91.86
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.21	7.99	10.64	6.20
Net Income	-$105.62M	$23.81M	$3.60B	$331.63M
7 Day Performance	N/A	-1.92%	-1.41%	-1.54%
1 Month Performance	N/A	1.88%	0.97%	-1.17%
1 Year Performance	-77.61%	43.58%	24.23%	17.81%

Applied Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLT Applied Therapeutics	1.3463 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
ANVS Annovis Bio	2.482 of 5 stars	$1.75 -3.1%	$11.67 +568.6%	-36.2%	$62.36M	N/A	N/A	3
CING Cingulate	2.6179 of 5 stars	$4.43 -3.5%	$27.33 +517.0%	-11.8%	$61.82M	N/A	N/A	20
CRDF Cardiff Oncology	3.2106 of 5 stars	$0.87 -1.7%	$7.50 +757.6%	-80.4%	$60.80M	$590K	N/A	20
OKYO OKYO Pharma	4.1041 of 5 stars	$1.38 -7.4%	$5.67 +310.6%	-54.2%	$60.43M	N/A	N/A	7	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Applied Therapeutics (APLT) Competitors

APLT vs. ANVS, CING, CRDF, OKYO, and TCRX

How does Applied Therapeutics compare to Annovis Bio?

Summary

How does Applied Therapeutics compare to Cingulate?

Summary

How does Applied Therapeutics compare to Cardiff Oncology?

Summary

How does Applied Therapeutics compare to OKYO Pharma?

Summary

How does Applied Therapeutics compare to TScan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Applied Therapeutics (APLT) Competitors

APLT vs. ANVS, CING, CRDF, OKYO, and TCRX

How does Applied Therapeutics compare to Annovis Bio?

Which has more volatility and risk, ANVS or APLT?

Does the media prefer ANVS or APLT?

Which has preferable valuation & earnings, ANVS or APLT?

Is ANVS or APLT more profitable?

Do insiders & institutionals believe in ANVS or APLT?

Do analysts rate ANVS or APLT?

Summary

How does Applied Therapeutics compare to Cingulate?

Which has more volatility and risk, APLT or CING?

Is APLT or CING more profitable?

Do insiders & institutionals believe in APLT or CING?

Does the media favor APLT or CING?

Do analysts recommend APLT or CING?

Which has higher valuation & earnings, APLT or CING?

Summary

How does Applied Therapeutics compare to Cardiff Oncology?

Do institutionals & insiders believe in APLT or CRDF?

Which has stronger earnings & valuation, APLT or CRDF?

Is APLT or CRDF more profitable?

Does the media prefer APLT or CRDF?

Do analysts recommend APLT or CRDF?

Which has more volatility and risk, APLT or CRDF?

Summary

How does Applied Therapeutics compare to OKYO Pharma?

Do institutionals and insiders hold more shares of APLT or OKYO?

Do analysts prefer APLT or OKYO?

Does the media prefer APLT or OKYO?

Which has better valuation and earnings, APLT or OKYO?

Which has more risk and volatility, APLT or OKYO?

Is APLT or OKYO more profitable?

Summary

How does Applied Therapeutics compare to TScan Therapeutics?

Which has more risk & volatility, TCRX or APLT?

Do insiders and institutionals believe in TCRX or APLT?

Is TCRX or APLT more profitable?

Which has stronger earnings & valuation, TCRX or APLT?

Do analysts prefer TCRX or APLT?

Does the media refer more to TCRX or APLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools